| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.pfizerltd.co.in | |
| Market Cap | 19,191.86 Cr. | |
| Enterprise Value(EV) | 17,302.20 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 109.76 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 38.22 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 743.86 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 5.64 | Calculated using Price: 4,195.15 |
| Dividend Yield | 1.67 | Period Ending 2023-03 |
| No. of Shares Subscribed | 4.57 Cr. | 45,747,732 Shares |
| FaceValue | 10 | |
| About Pfizer Ltd. | ||
| Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products. Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis. | ||
| 1 Day |
|
+1.22% |
| 1 Week |
|
+1.95% |
| 1 Month |
|
-3.57% |
| 3 Month |
|
-2.23% |
| 6 Month |
|
+5.19% |
| 1 Year |
|
+11.26% |
| 2 Year |
|
-2.82% |
| 5 Year |
|
+34.25% |
| 10 Year |
|
+222.15% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 7.63 | 14.75 | 14.7 | 14.11 | 15.07 | 15.89 | 17.19 | 23.3 | 20.55 | |
| Return on Capital Employed (%) | 18.19 | 22.78 | 22.62 | 21.49 | 23.22 | 20.38 | 23.62 | 29.78 | 27.56 | |
| Return on Assets (%) | 5.75 | 11.22 | 10.95 | 10.36 | 11.25 | 12.2 | 13 | 17.24 | 16.09 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1,973 | 2,164 | 2,419 | 2,683 | 3,011 | 3,395 | 2,393 | 2,864 | 3,207 | 3,273 | |
| Non Curr. Liab. | -35 | 66 | 62 | 52 | 37 | 136 | 85 | 136 | 38 | 24 | |
| Curr. Liab. | 609 | 658 | 780 | 954 | 892 | 873 | 774 | 853 | 657 | 614 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 2,547 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 3,911 | |
| Non Curr. Assets | 1,295 | 1,256 | 1,210 | 1,273 | 1,225 | 1,357 | 1,344 | 1,457 | 1,378 | 1,362 | |
| Curr. Assets | 1,252 | 1,614 | 2,033 | 2,403 | 2,702 | 3,013 | 1,873 | 2,361 | 2,493 | 2,549 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 2,547 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 3,911 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,219 | |
| Other Income | 72 | 87 | 101 | 114 | 167 | 184 | 81 | 63 | 101 | 137 | |
| Total Income | 1,925 | 2,099 | 2,067 | 2,083 | 2,249 | 2,336 | 2,320 | 2,674 | 2,526 | 2,356 | |
| Total Expenditure | -1,474 | -1,579 | -1,616 | -1,468 | -1,516 | -1,579 | -1,526 | -1,775 | -1,616 | -1,591 | |
| PBIDT | 451 | 520 | 451 | 615 | 733 | 757 | 794 | 899 | 910 | 765 | |
| Interest | -2 | -1 | -2 | -1 | -2 | -11 | -15 | -11 | -13 | -11 | |
| Depreciation | -131 | -58 | -63 | -66 | -71 | -103 | -109 | -115 | -106 | -75 | |
| Taxation | -138 | -165 | -180 | -188 | -231 | -133 | -171 | -160 | -200 | -165 | |
| Exceptional Items | -80 | 10 | 130 | 33 | -12 | ||||||
| PAT | 100 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 502 | |
| Adjusted EPS | 22 | 67 | 74 | 79 | 94 | 111 | 109 | 134 | 136 | 110 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 132 | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | |
| Cash Fr. Inv. | 103 | -89 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | |
| Cash Fr. Finan. | -1,360 | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | |
| Net Change | -1,125 | 23 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | |
| Cash & Cash Eqvt | 308 | 488 | 71 | 68 | 51 | 74 | 1,764 | 151 | 63 | 37 |
|
Fri, 26 Apr 2024
Loss/Duplicate-Share Certificate-XBRL Pfizer Limited has informed the Exchange about Loss of share certificates |
|
Fri, 26 Apr 2024
Loss of Share Certificates Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Limited has received request for issue of duplicate Share Certificate from Shareholder.We shall issue the Letter of Confirmation upon completion of necessary formalities by the shareholder. |
|
Thu, 25 Apr 2024
Loss of Share Certificates Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Limited has received request for issue of duplicate Share Certificate(s) from Shareholder(s).We shall issue the Letter of Confirmation(s) upon completion of necessary formalities by the shareholder(s). |
| Fri, 26 Apr 2024 |
Closing Above Previous High
|
Close Within 52 Week Low Zone
|
MFI Bullish
|
Close Above Last Week High
|
Close Crossing Last Week High
|
